Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase

Southlake, Texas, September 24, 2026 (PR NEWSWIRE) – Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation in the Oppenheimer Private Life Sciences Showcase, taking place virtually on September 29, 2026.

Bhupinder Singh, MD, FASN, FNKF, Chief Medical Officer of Renibus, will present virtually on Tuesday, September 29, 2026 at 11:15 am Eastern Standard Time.  Company management will also meet with investors in one-on-one meetings during the conference.

About Renibus Therapeutics

Renibus Therapeutics® is a clinical late-stage biopharmaceutical company focused on the prevention and treatment of cardiac, renal, and metabolic diseases. Renibus’ lead program, veverimer, is currently in Phase 3 development for the treatment of metabolic acidosis in adults with chronic kidney disease. The Company’s second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial evaluating RBT-1 in patients undergoing cardiac surgery.  Results from this trial suggest that further development in risk-enriched patients may be warranted and is currently under evaluation.  RBT-1 has received Breakthrough and Fast Track designations from the FDA.

For more information, please visit the Company’s website at www.Renibus.com and engage with us on LinkedIn.

Investor and Media Contact:

Amy Conrad
Juniper Point
amy@juniper-point.com
858-914-1962

Business Development Contact

Jamie Donadio
CFO, Renibus
jdonadio@renibus.com